The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
 
Silvia Stacchiotti
Honoraria - Gentili; GlaxoSmithKline; Peerview; PharmaMar; Servier
Consulting or Advisory Role - Bayer; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; Merck Serono; Orion; Parabilis; Pharmaessentia; SERVIER; Sun Pharma
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Merck Serono; Novartis (Inst); PharmaMar (Inst); SERVIER; SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Jonathan Trent
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; SERVIER
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Boehringer Ingelheim; Deciphera; Ipsen; Replimune
Research Funding - Advenc (Inst); Ascentage Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Karyopharm Therapeutics (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Delcath Systems; Fortvita Biosciences; Immunocore; SERVIER; SpringWorks Therapeutics; Treeline Biosciences; TuHura
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); GenVivo (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Immunocore (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Krystal Biotech (Inst); Macrogenics (Inst); Nested Therapeutics (Inst); Pierre Fabre (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - immatics
 
Rashmi Chugh
Consulting or Advisory Role - Cogent Biosciences; Deciphera; Recordati
Research Funding - Astex Pharmaceuticals (Inst); Cogent Biosciences (Inst); GlaxoSmithKline (Inst); Immunome (Inst); InhibRx (Inst); Kronos Bio (Inst); Kura Oncology (Inst); Novel Nobility (Inst); PharmaMar (Inst); Polaris (Inst); PTC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Expert Testimony - Reminger Co, LPA
 
Zhengfu Fan
No Relationships to Disclose
 
Robin Jones
Consulting or Advisory Role - Adaptimmune; Adcendo; Agenus; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Cogent Biosciences; Daiichi Sankyo; Deciphera; Eisai; Epizyme; GlaxoSmithKline; IDRx; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; NewBay Pharma; Orion Health; PharmaMar; PTC Therapeutics; SERVIER; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Brian Van Tine
Leadership - Polaris
Honoraria - Beijing Biostar Pharmaceuticals Co., Ltd.; Oncology Education; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; Adaptimmune; Advenchen Laboratories; Boxer Capital LLC; Crisper Therapeutics; Daiihi Sankyo; Deciphera; Galapagos NV; Hinge Bio; Kronos Bio, Inc.; Putnam Associates; Salarius Pharmaceuticals, INc.; Syneos Health
Research Funding - Polaris
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Nam Bui
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Checkpoint Capital; EcoR1 Capital; Immunome
Research Funding - SpringWorks Therapeutics
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Zan Shen
No Relationships to Disclose
 
Bruno Vincenzi
No Relationships to Disclose
 
Vicki Keedy
Employment - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Deciphera
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); Shanghai Pharma (Inst); Tizona Therapeutics, Inc. (Inst); TRACON Pharma (Inst)
 
Seth Pollack
Consulting or Advisory Role - AADi; Apexigen; Attivare Therapeutics; Bayer; Boehringer Ingelheim; Cogent Medicine; Daichii Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Ipsen; Obsidian Therapeutics; Replimune; Sensei Biotherapeutics; T-Knife
Speakers' Bureau - Deciphera; SpringWorks Therapeutics
Research Funding - Obsidian Therapeutics (Inst)
 
Brittany Siontis
Consulting or Advisory Role - Deciphera (Inst); Ratio (Inst)